![](/img/cover-not-exists.png)
Analysis of circulating tumor DNA (ctDNA) from the phase II BLC2001 trial of erdafitinib in locally advanced or metastatic urothelial carcinoma (mUC) to identify markers of intrinsic resistance to fibroblast growth factor receptor (FGFR)-targeted therapy
Siefker-Radtke, A.O., Loriot, Y., Necchi, A., Huddart, R.A., Burgess, E.F., Rezazadeh, A., O'Hagan, A., De Porre, P., Avadhani, A., Monga, M., Cherkas, Y., Moy, C.H., Santiago-Walker, A.Volume:
31
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.08.823
Date:
September, 2020
File:
PDF, 79 KB
2020